Clinical Trials
15
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (15 trials with phase data)• Click on a phase to view related trials
A Phase 2 Study of CRD-4730 in CPVT
- Conditions
- Catecholaminergic Polymorphic Ventricular Tachycardia
- First Posted Date
- 2024-10-26
- Last Posted Date
- 2025-08-19
- Lead Sponsor
- Cardurion Pharmaceuticals Inc.
- Target Recruit Count
- 6
- Registration Number
- 2024-515564-32-00
- Locations
- 🇮🇹
Istituti Clinici Scientifici Maugeri S.p.A. Societa' Benefit In Forma Abbreviata Istituti Clinici Scientifici Maugeri S.p.A. Sb O Anche Ics Maugeri S.p.A. Sb O Maugeri S.p.A. Sb, Pavia, Italy
🇪🇸Hospital Sant Joan De Deu Barcelona, Esplugues De Llobregat, Spain
🇳🇱Amsterdam UMC Stichting, Amsterdam, Netherlands
A Phase 2 Clinical Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Preserved Ejection Fraction
- Conditions
- chronic heart failure
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-01-22
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- Cardurion Pharmaceuticals Inc.
- Target Recruit Count
- 128
- Registration Number
- 2023-508737-13-00
- Locations
- 🇨🇿
Edumed s.r.o., Hradec Kralove, Czechia
🇨🇿Vseobecna Fakultni Nemocnice V Praze, Prague, Czechia
🇨🇿Fakultni Nemocnice Brno, Brno, Czechia
A Study to Assess Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Reduced Ejection Fraction (Cycle-1-REF)
- Conditions
- Heart FailureHeart Failure With Reduced Ejection FractionCardiovascular DiseasesHeart Diseases
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-01-22
- Last Posted Date
- 2025-08-05
- Lead Sponsor
- Cardurion Pharmaceuticals, Inc.
- Target Recruit Count
- 557
- Registration Number
- NCT06215911
- Locations
- 🇬🇧
Cardurion Investigative Site, Southampton, United Kingdom
🇧🇪Cardurion Investigational Site, Brugge, Belgium
🇬🇪Cardurion Investigative Site 2, Tbilisi, Georgia
Effectiveness of CRD-4730 in Participants With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
- Conditions
- CPVT1Heart Defects, CongenitalHeart DiseasesVentricular Tachycardia
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-08-22
- Last Posted Date
- 2025-07-14
- Lead Sponsor
- Cardurion Pharmaceuticals, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT06005428
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸Cleveland Clinic Children's Hospital, Cleveland, Ohio, United States
🇺🇸Baylor College of Medicine, Houston, Texas, United States
Effect of Coadministration of Itraconazole on the Pharmacokinetics of CRD-740
- Conditions
- PharmacokineticsCardiovascular DiseasesClinical PharmacologyHeart Failure
- Interventions
- First Posted Date
- 2022-06-29
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Cardurion Pharmaceuticals, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT05437094
- Locations
- 🇺🇸
Cardurion Investigative Site, Dallas, Texas, United States
- Prev
- 1
- 2
- 3
- Next
News
Cardurion Completes Enrollment in Phase 2 Trials for Novel Heart Failure Drug CRD-750
Cardurion Pharmaceuticals has completed enrollment in two Phase 2 trials evaluating CRD-750, the first clinical-stage PDE9 inhibitor for chronic heart failure treatment.
Cardurion Pharmaceuticals Recognized as a Top Biotech for Cardiovascular Therapeutics
Cardurion Pharmaceuticals has been named one of the Endpoints 11 most promising private biotechnology companies of 2024, recognizing its innovative approach to cardiovascular disease treatment.